Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02831582 · ClinicalTrials.gov registry record · NA
Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 75
- Enrollment target
NCT02831582 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 75 participants.
The verdict
NCT02831582, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
Study Summary
This clinical trial studies the use of omega-3 fatty acid supplementation in preventing aromatase inhibitor-induced toxicity in patients with stage I-III breast cancer. An omega-3 supplementation may help relieve moderate to severe bone pain and improve joint symptoms caused by aromatase inhibitor-induced arthralgias.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Omega-3 Fatty Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2021-12-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02831582
The ClinicalTrials.gov registry entry for NCT02831582 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02831582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02831582 about?
NCT02831582 is a clinical study titled "Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer". This clinical trial studies the use of omega-3 fatty acid supplementation in preventing aromatase inhibitor-induced toxicity in patients with stage I-III breast cancer. An omega-3 supplementation may help relieve moderate to severe bone pain and improve joint symptoms caused by aromatase inhibitor-i...
What is the current status of trial NCT02831582?
This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2016-10-12. Estimated completion is 2021-12-11.
What interventions are being tested in trial NCT02831582?
The interventions under investigation include: Placebo (OTHER), Omega-3 Fatty Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02831582?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.